Browse related articles
Over 100 anaesthesiologists and intensivists from UAE, Saudi Arabia and other Middle East countries attended the seminar to hear about the ground-breaking treatment.
Precedex (Dexmedetomidine HCI) is a unique new sedative agent that can be used on patients in the intensive care unit. It works as both a sedative and an analgesic, and does not cause respiratory depression. Precedex has been approved by the FDA.
Dr. Mohammed Seraj, Chairman of the Saudi Anaesthetic Association said, ' Precedex represents a significant step forward in the sedation field, and is sure to be widely adopted in hospitals across the region. It has a unique sedative quality, because patients can be clinically sedated, but still rousable when stimulated. This means they are more capable of communicating their needs.'
Prof. Jean Mantz, Professor of Anaesthesiology and Clinical Care at Bichet Hospital, France, added, 'Precedex's dual action makes it unique in the field. Another important feature is the fact that it doesn't have any adverse effects on the respiratory system. This means that there are fewer complications, and this can mean a shorter stay in the intensive care unit for many patients.'
Abbott launches new sedative in the Middle East
Abbott Laboratories has launched a new sedative in the Middle East. The product was launched at a symposium organised by the Saudi Anaesthetic Association in Dubai.
- United Arab Emirates: Wednesday, July 03 - 2002 at 13:29
- PRESS RELEASE
- ADD ARTICLE TO
-
Facebook
del.icio.us
Digg
Log in to request more information from Abbott LaboratoriesNotes and media contacts
For further information, please contact: Lorraine Chandler/Ghada Kammoun,Bates PanGulf PR, phone 04 2219065/ 050 5532817
Posted by Anne-Birte Stensgaard, News EditorWednesday, July 03 - 2002 at 13:29 UAE local time (GMT+4)
Replication or redistribution in whole or in part is expressly prohibited without the prior written consent of AME Info FZ LLC / Emap Limited.
This Article was updated on Sunday, October 26 - 2003
Disclaimer:
Articles in this section are primarily provided directly by the companies appearing or PR agencies which are solely responsible for the content. The companies concerned may use the above content on their respective web sites provided they link back to http://www.ameinfo.com
Any opinions, advice, statements, offers or other information expressed in this section of the AME Info Web site are those of the authors and do not necessarily reflect the views of AME Info FZ LLC / Emap Limited. AME Info FZ LLC / Emap Limited is not responsible or liable for the content, accuracy or reliability of any material, advice, opinion or statement in this section of the AME Info Web site.
For details about submitting your stories, please read the guide - all content published is subject to our terms and conditions
Articles in this section are primarily provided directly by the companies appearing or PR agencies which are solely responsible for the content. The companies concerned may use the above content on their respective web sites provided they link back to http://www.ameinfo.com
Any opinions, advice, statements, offers or other information expressed in this section of the AME Info Web site are those of the authors and do not necessarily reflect the views of AME Info FZ LLC / Emap Limited. AME Info FZ LLC / Emap Limited is not responsible or liable for the content, accuracy or reliability of any material, advice, opinion or statement in this section of the AME Info Web site.
For details about submitting your stories, please read the guide - all content published is subject to our terms and conditions
Web Feeds